Axogen Reports Strong Q4 & Full-Year 2025 Results, Guides for 18%+ Revenue Growth in 2026

summarizeSummary

This 8-K provides the final, strong fourth quarter and full-year 2025 financial results, confirming the preliminary positive trends reported earlier. The company achieved over 20% revenue growth for both periods and reported improved adjusted net income and EBITDA. Key strategic achievements, including the FDA Biologics License Application (BLA) approval for Avance® and significant CMS reimbursement increases, are highlighted as foundational for future growth. The successful public offering and subsequent debt repayment have also significantly strengthened the balance sheet. The positive 2026 guidance, projecting at least 18% revenue growth and free cash flow positivity, indicates continued operational momentum and financial health. Investors should view these results and outlook as a strong signal of the company's execution and market position.

check_boxKey Events

• Strong 2025 Financial Performance

  Fourth quarter revenue increased 21.3% to $59.9 million, and full-year revenue grew 20.2% to $225.2 million, driven by broad-based double-digit growth across all markets. Adjusted net income for the full year was $14.4 million, up from $5.9 million in 2024.

• Positive 2026 Financial Guidance

  The company expects at least 18% revenue growth, targeting $265.7 million for the full year, with gross margins between 74% and 76%, and anticipates being free cash flow positive.

• Strategic Milestones Achieved

  Highlighted the FDA Biologics License Application (BLA) approval for Avance® in December 2025 and the new CMS Level 3 Nerve Procedure Code effective January 2026, which significantly increases reimbursement rates for Avance® procedures.

• Strengthened Balance Sheet

  Confirmed the closing of an upsized public offering on January 23, 2026, raising $133.3 million in net proceeds, with $69.7 million used to fully repay and terminate the Oberland loan facility.

auto_awesomeAnalysis

This 8-K provides the final, strong fourth quarter and full-year 2025 financial results, confirming the preliminary positive trends reported earlier. The company achieved over 20% revenue growth for both periods and reported improved adjusted net income and EBITDA. Key strategic achievements, including the FDA Biologics License Application (BLA) approval for Avance® and significant CMS reimbursement increases, are highlighted as foundational for future growth. The successful public offering and subsequent debt repayment have also significantly strengthened the balance sheet. The positive 2026 guidance, projecting at least 18% revenue growth and free cash flow positivity, indicates continued operational momentum and financial health. Investors should view these results and outlook as a strong signal of the company's execution and market position.